Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
    • Semiconductors
  • Disclosures
    • Semiconductors
    • Energy
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form
  • [Disclosure] Celltrion (068270) – Additional Listing (Bonus Issue) / 2026-06-25 Disclosures
  • [Disclosure] Hanwha Systems (272210) – Matters Related to Sustainability Report (Voluntary Disclosure) / 2026-06-29 Disclosures
  • [Disclosure] Hanwha Aerospace (012450) – Trading Suspension and Resumption of Stock Futures and Options / 2024-08-22 Disclosures
  • [Disclosure] SK Hynix (000660 / SKHY) – Setting of Shareholder Register Closure Period or Record Date / 2024-09-12 Semiconductors
  • [Disclosure] Hanwha Ocean (042660) – (Correction) Sales and Supply Contract / 2025-12-04 Disclosures
  • [Research] SK hynix (000660 / SKHY) – Meritz | Pre-Order Demand · LTA · Earnings Visibility / 2025-10-29 Semiconductors
  • [Disclosure] Hyundai Motor (005380) – Outlook on Operating Performance / 2026-01-05 Disclosures
  • [Disclosure] Hanwha Aerospace (012450) – Occurrence of Serious Accident / 2026-01-30 Disclosures

[Disclosure] Celltrion (068270) – Decision on Stock Dividend / 2024-12-13

Posted on December 13, 2024August 6, 2026 By K-STOCK Editor

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Celltrion decided to distribute a stock dividend of 0.05 common shares per common share (totaling 10,251,543 shares) with a record date of December 31, 2024.

📊 Key Disclosure Content & Financial Highlights

  1. Overview
  • Company: Celltrion, Inc. (Stock Code: 068270)
  • Disclosure Type: Decision on Stock Dividend
  • Board Resolution Date: 2024-12-13
  • Record Date: 2024-12-31
  1. Stock Dividend Details
  • Stock Dividend per Share: 0.05 common shares
  • Total Dividend Shares: 10,251,543 common shares
  • Total Issued Shares: 217,078,554 common shares
  • Fractional Shares Settlement: Fractional shares under 1 share will be converted to and paid in cash based on the closing stock price on the business day prior to the 34th Annual General Meeting of Shareholders.
  1. Key Details & Investment Risks
  • The stock dividend proposal will be submitted to the 34th Annual General Meeting of Shareholders and is subject to change depending on shareholder voting results.
  • Total dividend shares were calculated based on 205,030,873 shares, excluding 12,047,681 treasury shares (including planned acquisition volume) from the total issued shares of 217,078,554.
  • Treasury share counts may vary depending on appraisal rights exercises and will be re-disclosed if changes occur upon reviewing the shareholder register on the record date (2024-12-31).

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of Shareholder Meeting Approval and Dividend Finalization

This disclosure serves as official notification regarding the board resolution to distribute a stock dividend of 0.05 common shares per share for FY2024. Tracking whether the dividend proposal receives final approval at the upcoming 34th Annual General Meeting of Shareholders is important for verifying the final execution of the shareholder return policy. Relevant updates can be confirmed through subsequent shareholder meeting outcome disclosures or periodic filings.

📢 Disclaimer & Source Notice

Source: This content was structured and generated based on official disclosure data from the Financial Supervisory Service’s DART system.

Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Plan for CT-P51 (Keytruda Biosimilar) in Europe (Part 1 & 2) / 2024-12-13
Next Post: [Disclosure] Celltrion (068270) – Decision on Cash Dividend / 2024-12-13

Related Posts

  • [Disclosure] Hana Micron (067310) – Additional Listing (Exercise of Stock Options) / 2026-06-17 Semiconductors
  • [Disclosure] Hanwha Aerospace (012450) – Decision on Cash/In-Kind Dividend / 2024-02-23 Disclosures
  • [Disclosure] Hanwha Aerospace (012450) – Setting of Record Date / 2025-03-20 Disclosures
  • [Disclosure] Hanwha Ocean (042660) – Loan Decision / 2025-03-21 Disclosures
  • [Disclosure] Celltrion (068270) – Results of Annual General Meeting of Shareholders / 2024-03-26 Disclosures
  • [Disclosure] Hanwha Aerospace (012450) – Investor Relations (IR) Announcement / 2024-10-15 Disclosures
  • [Research] SK hynix (000660 / SKHY) – IBK Securities | AI Servers · Server DRAM · Supply Tightness / 2026-04-15 RESEARCH
  • [Disclosure] Hanwha Systems (272210) – Investor Relations (IR) Holding / 2025-10-31 Disclosures
  • [Disclosure] Samsung Biologics (207940) – Provisional Operating Performance (Fair Disclosure) / 2025-10-28 Disclosures
  • [Disclosure] Hyundai Motor (005380) – Investor Relations (IR) Announcement / 2026-02-26 Disclosures
  • [Disclosure] SK Square (402340) – (Correction) Decision on Issuance of Depositary Receipts / 2026-07-10 Disclosures
  • [Disclosure] HPSP (403870) – Setting of Record Date or Period for Closure of Shareholders Register / 2025-09-26 Semiconductors
  • [Disclosure] Celltrion (068270) – Results of Annual General Meeting of Shareholders / 2025-03-25 Disclosures
  • [Research] SK hynix (000660 / SKHY) – Hanwha | HBM Negotiations · AI Growth · DRAM Supply Risk / 2025-07-25 RESEARCH

Copyright © 2026 K-Stock Briefing.

Powered by PressBook News Dark theme